House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Hepatology

Hepatitis B (chronic): diagnosis and management

NICE · 2017 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This focused summary of NICE CG165 covers chronic hepatitis B assessment, specialist referral, fibrosis evaluation, monitoring and surveillance. The guideline contains older retained treatment pathways and later linked appraisals; those should not be mistaken for a complete contemporary antiviral sequence. The priorities here are to establish viral and liver-disease status, recognize decompensation, support adherence and maintain structured follow-up.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Explain the disease and arrange specialist assessment

  • Explain the natural history, transmission, lifestyle considerations, family planning, treatment goals and the importance of monitoring and adherence. Offer a personalized care plan outlining treatment and long-term follow-up. [1]
  • In HBsAg-positive adults, initial assessment includes HBeAg/anti-HBe, HBV DNA, anti-HBc IgM and testing for hepatitis C, hepatitis D and HIV. The guideline also lists hepatitis A immunity, liver biochemistry, albumin, bilirubin, blood count, prothrombin time, ultrasound and AFP. [1]
  • Refer every HBsAg-positive adult to a hepatologist or a gastroenterology/infectious-disease specialist with hepatology expertise, supplying initial results. HBsAg-positive children need an appropriate paediatric specialist and their initial investigations. [1]
  • Arrange specialist assessment for an HBsAg-positive pregnant woman within 6 weeks of the screening result, allowing timely planning of antenatal treatment and prevention of transmission. [1]
  • Refer decompensated liver disease immediately. Warning manifestations include ascites, encephalopathy or gastrointestinal bleeding. [1]

Assess fibrosis and interpret the tests carefully

  • Offer transient elastography as the initial specialist liver-disease assessment in adults. Explain test accuracy, limitations and risks, and account for factors affecting stiffness, including fatty liver or alcohol-related disease. [1]
  • Offer annual elastography reassessment to adults not receiving antiviral therapy. In children, discuss the potential value and risks of liver biopsy with the child and family when assessing treatment need. [1]
  • Do not use HBV genotype testing to determine initial treatment. Discuss treatment benefits, harms and prognosis, reassess HIV exposure risk and repeat testing if needed; antiviral initiation belongs with a professional experienced in viral hepatitis. [1]
  • For adults with cirrhosis and detectable HBV DNA, the guideline offers antiviral treatment regardless of HBeAg, DNA concentration or ALT. This indication does not replace the broader eligibility assessment or current treatment-choice guidance. [1]

Monitor untreated disease rather than assuming inactivity persists

  • In the guideline’s HBeAg-positive immune-tolerant adult group—active replication with ALT below 30 IU/L in males or 19 IU/L in females—check ALT every 24 weeks. If ALT rises, check every 12 weeks on at least 3 consecutive occasions. [1]
  • For inactive adult HBV, defined here by HBeAg negativity on 2 tests, ALT below 30 IU/L in males or 19 IU/L in females and DNA below 2,000 IU/mL, monitor ALT and HBV DNA every 48 weeks. With cirrhosis and undetectable DNA, consider more frequent checks, such as every 12–24 weeks. [1]
  • After treatment-related HBeAg seroconversion, monitor HBeAg, anti-HBe, HBV DNA and liver function at 4, 12 and 24 weeks and then every 6 months. [1]

Monitor toxicity and virological response

  • For compensated disease on entecavir or lamivudine, check blood count, liver function and renal function before treatment, after 4 weeks and then every 3 months. Check HBV DNA, quantitative HBsAg and HBeAg at baseline, 12, 24 and 48 weeks, then every 6 months for response and adherence. [1]
  • For compensated disease on tenofovir disoproxil, check blood count, liver and renal function, urine protein/creatinine and phosphate before treatment, after 4 weeks and every 3 months. Virological response and adherence monitoring also remain necessary. [1]
  • Decompensated disease on entecavir or lamivudine needs closer follow-up: the guideline specifies baseline and weekly assessment of relevant blood count, liver, renal, clotting and virological measures until compensation permits the less intensive schedule. [1]

Maintain surveillance in the specified higher-risk groups

  • For adults with significant fibrosis—METAVIR at least F2 or Ishak at least 3—or cirrhosis, the guideline recommends hepatic ultrasound and AFP every 6 months for HCC surveillance. [1]
  • Without significant fibrosis or cirrhosis, this guideline also considers surveillance every 6 months when age is above 40, family history of HCC is present and HBV DNA is at least 20,000 IU/mL. These are combined criteria within the captured NICE pathway, not a complete modern HCC risk model. [1]

Limitations and use

  • This selected summary covers assessment, monitoring and surveillance, not the complete antiviral treatment algorithm. Older interferon-first sequences, pregnancy viral-load thresholds, coinfection regimens, reactivation prophylaxis and treatment-stopping rules are not reproduced as current universal practice.
  • Apply the appropriate contemporary HBV guidance and specialist assessment for treatment eligibility, pregnancy prophylaxis, immunosuppression and drug choice. The captured NICE thresholds and follow-up intervals must not exclude a person eligible under a newer or different regional pathway.
  • Listed monitoring is not exhaustive for every antiviral or patient group. HCC surveillance requires broader individualized risk assessment; this summary does not establish that anyone outside the listed groups should be excluded.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Hepatitis B (chronic): diagnosis and management

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
26 June 2013
Publisher’s latest update
20 October 2017
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Explain the disease and arrange specialist assessment
  • Assess fibrosis and interpret the tests carefully
  • Monitor untreated disease rather than assuming inactivity persists
  • Monitor toxicity and virological response
  • Maintain surveillance in the specified higher-risk groups
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House